Waldencast plc, through its Obagi Medical division, has announced a partnership with Aesthetic Record to support the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. The collaboration will leverage Aesthetic Record's advanced EMR and analytics platform to gather real-world evidence on Obagi’s new injectable products, aiming to enhance operational efficiency and patient outcomes across thousands of aesthetic practices.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655619-en) on February 17, 2026, and is solely responsible for the information contained therein.